14 research outputs found
Intracellular fibril formation, calcification, and enrichment of chaperones, cytoskeletal, and intermediate filament proteins in the adult hippocampus CA1 following neonatal exposure to the nonprotein amino acid BMAA
Meccanismi di vulnerabilità dei neuroni dopaminergici mesencefalici di ratto esposti a fattori neurotossici ambientali
Substantia nigra control of basal ganglia nuclei
Abstract. The substantia nigra, located in the ventral mesencephalon,
is one of the five nuclei that constitute the basal
ganglia circuit, which controls voluntary movements.
It is divided into the pars compacta and the pars reticulata,
which mainly contain dopaminergic and GABAergic
cells respectively. Here we overview the electrophysiological
properties of these substantia nigra neurons in the pars
compacta and reticulata, together with their synaptic connections,
and discuss the functional effects of dopaminergic
and GABAergic inputs within the basal ganglia. We also
examine the phenomenon that when a deficiency of dopamine
(DA) occurs (e.g. in Parkinson’s disease), there is an
aberrant synaptic plasticity in the basal ganglia.
Moreover, we point out that the appearance of an altered
pattern of neuronal firing (beta-oscillations) and synchrony
among neurons in the subthalamic nucleus, the internal
globus pallidus, and the substantia nigra pars reticulata has
been related to motor symptoms and possibly, persistent
degeneration of DA-containing neurons.
Finally, we believe that, based on pathophysiological
data, new and significant targets for therapeutic intervention
can be identified and tested
The midbrain slice preparation. An in vitro model to select potential anti-parkinsonian drugs?
Abstract.
Most anti-parkinsonian drugs produce a dopamine-like effect on single dopaminergic neurons. Using electrophysiological recordings, this effect is observed as an inhibition of the spontaneous firing activity. The firing activity of dopaminergic cells throughout dopamine-mediated mechanisms is inhibited not only by dopamine direct agonists but also by substances that increase the release or synthesis, or block the uptake or reduce degradation of dopamine in the brain. Here we propose the electrophysiological approach on dopaminergic neurons in in vitro slice
preparation as a preliminary tool for selecting new potential anti-parkinsonian agents, before they are tested in more complex animal models
Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta
1-Amino-3,5-dimethyl-adamantane (memantine) is a noncompetitive
N-methyl-D-aspartate (NMDA) receptor antagonist
used in clinical practice to treat neurodegenerative disorders
that could be associated with excitotoxic cell death. Because
memantine reduces the loss of dopamine neurons of
the substantia nigra pars compacta (SNc) in animal models of
Parkinson’s disease, we examined the effects of this drug on
dopamine cells of the SNc. Besides inhibition of NMDA
receptor-mediated currents, memantine (30 and 100 M)
increased the spontaneous firing rate of whole-cell recorded
dopamine neurons in a midbrain slice preparation. Occasionally,
a bursting activity was observed. These effects were
independent from the block of NMDA receptors and were
prevented in neurons dialyzed with a high concentration of
ATP (10 mM). An increase in firing rate was also induced by
the ATP-sensitive potassium (KATP) channel antagonist tolbutamide
(300 M), and this increase occluded further effects
of memantine. In addition, KATP channel-mediated outward
currents, induced by hypoxia, were inhibited by
memantine (30 and 100 M) in the presence of the NMDA
receptor antagonist (5S,10R)-()-5-methyl-10,11-dihydro-
5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801)
(10 M). An increase in the spontaneous firing rate by memantine
was observed in dopamine neurons recorded with
extracellular planar 8 8 multielectrodes in conditions of
hypoglycemia. These results highlight KATP channels as possible
relevant targets of memantine effects in the brain.
Moreover, in view of a proposed role of KATP conductances
in dopamine neuron degeneration, they suggest another
mechanism of action underlying the protective role of memantine
in Parkinson’s disease
Metabotropic glutamate receptor 1 mediates the electrophysiological and toxic actions of the cycad derivative beta-N-Methylamino-L-alanine on substantia nigra pars compacta DAergic neurons.
Amyotrophic lateral sclerosis-Parkinson dementia complex (ALS-PDC) is a neurodegenerative disease with ALS, parkinsonism, and Alzheimer's symptoms that is prevalent in the Guam population. beta-N-Methylamino alanine (BMAA) has been proposed as the toxic agent damaging several neuronal types in ALS-PDC, including substantia nigra pars compacta dopaminergic (SNpc DAergic) neurons. BMAA is a mixed glutamate receptor agonist, but the specific pathways activated in DAergic neurons are not yet known. We combined electrophysiology, microfluorometry, and confocal microscopy analysis to monitor membrane potential/current, cytosolic calcium concentration ([Ca(2+)](i)) changes, cytochrome-c (cyt-c) immunoreactivity, and reactive oxygen species (ROS) production induced by BMAA. Rapid toxin applications caused reversible membrane depolarization/inward current and increase of firing rate and [Ca(2+)](i) in DAergic neurons. The inward current (I(BMAA)) was mainly mediated by activation of metabotropic glutamate receptor 1 (mGluR1), coupled to transient receptor potential (TRP) channels, and to a lesser extent, AMPA receptors. Indeed, mGluR1 (CPCCOEt) and TRP channels (SKF 96365; Ruthenium Red) antagonists reduced I(BMAA), and a small component of I(BMAA) was reduced by the AMPA receptor antagonist CNQX. Calcium accumulation was mediated by mGluR1 but not by AMPA receptors. Application of a low concentration of NMDA potentiated the BMAA-mediated calcium increase. Prolonged exposure to BMAA caused significant modifications of membrane properties, calcium overload, cell shrinkage, massive cyt-c release into the cytosol and ROS production. In SNpc GABAergic neurons, BMAA activated only AMPA receptors. Our study identifies the mGluR1-activated mechanism induced by BMAA that may cause the neuronal degeneration and parkinsonian symptoms seen in ALS-PDC. Moreover, environmental exposure to BMAA might possibly also contribute to idiopathic PD
Metabotropic glutamate receptor 1 mediates the electrophysiological and toxic actions of the cycad derivative beta-N-Methylamino-L-alanine on substantia nigra pars compacta DAergic neurons.
Amyotrophic lateral sclerosis-Parkinson dementia complex (ALS-PDC) is a neurodegenerative disease with ALS, parkinsonism, and Alzheimer's symptoms that is prevalent in the Guam population. beta-N-Methylamino alanine (BMAA) has been proposed as the toxic agent damaging several neuronal types in ALS-PDC, including substantia nigra pars compacta dopaminergic (SNpc DAergic) neurons. BMAA is a mixed glutamate receptor agonist, but the specific pathways activated in DAergic neurons are not yet known. We combined electrophysiology, microfluorometry, and confocal microscopy analysis to monitor membrane potential/current, cytosolic calcium concentration ([Ca(2+)](i)) changes, cytochrome-c (cyt-c) immunoreactivity, and reactive oxygen species (ROS) production induced by BMAA. Rapid toxin applications caused reversible membrane depolarization/inward current and increase of firing rate and [Ca(2+)](i) in DAergic neurons. The inward current (I(BMAA)) was mainly mediated by activation of metabotropic glutamate receptor 1 (mGluR1), coupled to transient receptor potential (TRP) channels, and to a lesser extent, AMPA receptors. Indeed, mGluR1 (CPCCOEt) and TRP channels (SKF 96365; Ruthenium Red) antagonists reduced I(BMAA), and a small component of I(BMAA) was reduced by the AMPA receptor antagonist CNQX. Calcium accumulation was mediated by mGluR1 but not by AMPA receptors. Application of a low concentration of NMDA potentiated the BMAA-mediated calcium increase. Prolonged exposure to BMAA caused significant modifications of membrane properties, calcium overload, cell shrinkage, massive cyt-c release into the cytosol and ROS production. In SNpc GABAergic neurons, BMAA activated only AMPA receptors. Our study identifies the mGluR1-activated mechanism induced by BMAA that may cause the neuronal degeneration and parkinsonian symptoms seen in ALS-PDC. Moreover, environmental exposure to BMAA might possibly also contribute to idiopathic PD
Dual effects of l-DOPA on nigral dopaminergic neurons
L-DOPA (Levodopa) remains the gold standard for the treatment of motor symptoms of Parkinson's disease
(PD), despite indications that the drug may have detrimental effects in cell culture. Classically, L-DOPA
increases the production of dopamine (DA) in nigral dopaminergic neurons, while paradoxically inhibiting
the firing of these neurons due to activation of D2 autoreceptors by extracellularly released DA. Using a combination
of electrophysiology and calcium microfluorometry in brain slices, we have identified a novel effect
of L-DOPA on dopaminergic neurons when D2 receptors were blocked. Under these conditions, L-DOPA
(0.03–3 mM) evoked an excitatory effect consisting of two components. The ‘early’ component observed during
and immediately after application of the drug, was associated with increased firing, membrane depolarization
and inward current. This excitatory responsewas strongly attenuated by CNQX (10 μM), pointing to the involvement
of TOPA quinone, an auto-oxidation product of L-DOPA and a potent activator of AMPA/kainate receptors.
The ‘late’ phase of excitation persisted >30 min after brief L-DOPA application and was not mediated by
ionotropic glutamate receptors, nor by D1, α1-adrenergic, mGluR1 or GABAB receptors. It was eliminated by
carbidopa, demonstrating its dependence on conversion of L-DOPA to DA. Exogenous DA (50 μM) also evoked
a glutamate-receptor independent increase in firing and an inward current when D2 receptors were blocked.
In voltage-clamped neurons, both L-DOPA and DA produced a long-lasting increase in [Ca2+]i which was unaffected
by block of ionotropic glutamate receptors. These results demonstrate that L-DOPA has dual, inhibitory
and excitatory, effects on nigral dopaminergic neurons, and suggest that the excitation and calcium rise may
have long-lasting consequences for the activity and survival of these neurons when the expression or function
of D2 receptors is impaired
Properties of dopaminergic neurons in organotypic mesencephalic-striatal co-cultures--evidence for a facilitatory effect of dopamine on the glutamatergic input mediated by α-1 adrenergic receptors.
Organotypic cultures (OCs) have been widely used to investigate the midbrain dopaminergic system, but only a few studies focused on the functional properties of dopaminergic neurons and their synaptic inputs from dopaminergic and non-dopaminergic neuronsalso contained in such cultures. In addition, it is not clear whether the culturing process affects the intrinsic neuronal properties and the expression of specific receptors and transporters. We performed patch-clamp recordings from dopaminergic neurons in mesencephalic–striatal co-cultures obtained from transgenic mice expressing green fluorescent protein (GFP) under the tyrosine hydroxylase promoter. Some (10 ⁄ 44) GFP+ neurons displayed a bursting activity that renders the firing of these cells similar to that of the dopaminergic neurons in vivo. The culturing process reduced the hyperpolarization-activated current (Ih) and the expression of
D2 receptors. Downregulation of D2 receptor mRNA and protein was confirmed with reverse transcriptase polymerase chain reaction and Western blotting. Immunocytochemistry revealed that many synaptic terminals, most likely originating from dopaminergic neurons, co-expressed the dopamine (DA) transporter and the vesicular glutamate transporter-2, suggesting a co-release of DA and glutamate. Interestingly, exogenous DA decreased glutamate release in young cultures [days in vitro (DIV) < 20] by acting on pre-synaptic D2 receptors, while in older cultures (DIV > 26) DA increased glutamate release by acting on a-1 adrenoreceptors. The facilitatory effect of DA on glutamatergic transmission to midbrain dopaminergic neurons may be important in conditions when the expression of D2 receptors is compromised, such as long-term treatment with antipsychotic drugs. Our data show that midbrain OCs at DIV > 26 may provide a suitable model of such condition
Properties of dopaminergic neurons in organotypic mesencephalic-striatal co-cultures--evidence for a facilitatory effect of dopamine on the glutamatergic input mediated by \u3b1-1 adrenergic receptors.
Organotypic cultures (OCs) have been widely used to investigate the midbrain dopaminergic system, but only a few studies focused on the functional properties of dopaminergic neurons and their synaptic inputs from dopaminergic and non-dopaminergic neurons also contained in such cultures. In addition, it is not clear whether the culturing process affects the intrinsic neuronal properties and the expression of specific receptors and transporters. We performed patch-clamp recordings from dopaminergic neurons in mesencephalic-striatal co-cultures obtained from transgenic mice expressing green fluorescent protein (GFP) under the tyrosine hydroxylase promoter. Some (10/44) GFP+ neurons displayed a bursting activity that renders the firing of these cells similar to that of the dopaminergic neurons in vivo. The culturing process reduced the hyperpolarization-activated current (I(h) ) and the expression of D\u2082 receptors. Downregulation of D\u2082 receptor mRNA and protein was confirmed with reverse transcriptase polymerase chain reaction and Western blotting. Immunocytochemistry revealed that many synaptic terminals, most likely originating from dopaminergic neurons, co-expressed the dopamine (DA) transporter and the vesicular glutamate transporter-2, suggesting a co-release of DA and glutamate. Interestingly, exogenous DA decreased glutamate release in young cultures [days in vitro (DIV)<20] by acting on pre-synaptic D\u2082 receptors, while in older cultures (DIV>26) DA increased glutamate release by acting on \u3b1-1 adrenoreceptors. The facilitatory effect of DA on glutamatergic transmission to midbrain dopaminergic neurons may be important in conditions when the expression of D\u2082 receptors is compromised, such as long-term treatment with antipsychotic drugs. Our data show that midbrain OCs at DIV>26 may provide a suitable model of such conditions
